These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24118388)

  • 1. In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.
    Koyanagi T; Suzuki Y; Saga Y; Machida S; Takei Y; Fujiwara H; Suzuki M; Sato Y
    Cancer Sci; 2013 Dec; 104(12):1705-10. PubMed ID: 24118388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
    Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
    Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma.
    Xue X; Gao W; Sun B; Xu Y; Han B; Wang F; Zhang Y; Sun J; Wei J; Lu Z; Zhu Y; Sato Y; Sekido Y; Miao Y; Kondo Y
    Oncogene; 2013 Mar; 32(13):1724-34. PubMed ID: 22614011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.
    Norita R; Suzuki Y; Furutani Y; Takahashi K; Yoshimatsu Y; Podyma-Inoue KA; Watabe T; Sato Y
    Cancer Sci; 2017 Mar; 108(3):419-426. PubMed ID: 28064471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment.
    Koyanagi T; Suzuki Y; Komori K; Saga Y; Matsubara S; Fujiwara H; Sato Y
    Cancer Sci; 2017 Mar; 108(3):512-519. PubMed ID: 28032401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockout of vasohibin-2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer.
    Koyanagi T; Saga Y; Takahashi Y; Tamura K; Yoshiba T; Takahashi S; Taneichi A; Takei Y; Urabe M; Mizukami H; Fujiwara H
    Cancer Med; 2021 Apr; 10(8):2732-2739. PubMed ID: 33710778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma.
    Iida-Norita R; Kawamura M; Suzuki Y; Hamada S; Masamune A; Furukawa T; Sato Y
    Cancer Sci; 2019 Jul; 110(7):2296-2308. PubMed ID: 31074083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2.
    Tu M; Lu C; Lv N; Wei J; Lu Z; Xi C; Chen J; Guo F; Jiang K; Li Q; Wu J; Song G; Wang S; Gao W; Miao Y
    Cancer Lett; 2016 Dec; 383(2):272-281. PubMed ID: 27702660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasohibin-2 modulates tumor onset in the gastrointestinal tract by normalizing tumor angiogenesis.
    Kitahara S; Suzuki Y; Morishima M; Yoshii A; Kikuta S; Shimizu K; Morikawa S; Sato Y; Ezaki T
    Mol Cancer; 2014 May; 13():99. PubMed ID: 24885408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear vasohibin-2 promotes cell proliferation by inducing G0/G1 to S phase progression.
    Ge Q; Zhou J; Tu M; Xue X; Li Z; Lu Z; Wei J; Song G; Chen J; Guo F; Jiang K; Miao Y; Gao W
    Oncol Rep; 2015 Sep; 34(3):1327-36. PubMed ID: 26177649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of rabbit polyclonal antibodies against Vasohibin-2 for determination of its intracellular localization.
    Sun J; Tu M; Han B; Xue X; Zhang Y; Wei J; Chen J; Lu Z; An Y; Cai B; Lv N; Jiang K; Miao Y; Gao W
    Int J Oncol; 2013 Jul; 43(1):255-61. PubMed ID: 23615928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model.
    Masuda K; Tanabe K; Ujike H; Hinamoto N; Miyake H; Tanimura S; Sugiyama H; Sato Y; Maeshima Y; Wada J
    PLoS One; 2018; 13(4):e0195779. PubMed ID: 29641565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome.
    Kim JC; Kim KT; Park JT; Kim HJ; Sato Y; Kim HS
    Hepatogastroenterology; 2015; 62(138):251-6. PubMed ID: 25916042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasohibin‑2 promotes proliferation in human breast cancer cells via upregulation of fibroblast growth factor‑2 and growth/differentiation factor‑15 expression.
    Tu M; Liu X; Han B; Ge Q; Li Z; Lu Z; Wei J; Song G; Cai B; Lv N; Jiang K; Wang S; Miao Y; Gao W
    Mol Med Rep; 2014 Aug; 10(2):663-9. PubMed ID: 24920244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasohibin 2 decreases the cisplatin sensitivity of hepatocarcinoma cell line by downregulating p53.
    Li Z; Tu M; Han B; Gu Y; Xue X; Sun J; Ge Q; Miao Y; Qian Z; Gao W
    PLoS One; 2014; 9(3):e90358. PubMed ID: 24595063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells.
    Koyanagi T; Saga Y; Takahashi Y; Suzuki Y; Suzuki M; Sato Y
    Oncol Lett; 2013 Mar; 5(3):1058-1062. PubMed ID: 23426782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasohibin-2-Targeting Therapies for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Suzuki Y; Sato Y
    Tohoku J Exp Med; 2024 Mar; 262(3):163-171. PubMed ID: 38220168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of miR-200b/c by inhibiting vasohibin-2 in human retinal microvascular endothelial cells.
    Ding Y; Hu Z; Luan J; Lv X; Yuan D; Xie P; Yuan S; Liu Q
    Life Sci; 2017 Dec; 191():245-252. PubMed ID: 28882646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the vasohibin family in the regulation of fetoplacental vascularization and syncytiotrophoblast formation.
    Suenaga K; Kitahara S; Suzuki Y; Kobayashi M; Horie S; Sugawara J; Yaegashi N; Sato Y
    PLoS One; 2014; 9(9):e104728. PubMed ID: 25184477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
    Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
    Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.